Verstrepen Babs E, Boonstra André, Koopman Gerrit
Babs E Verstrepen, Gerrit Koopman, Department of Virology, Biomedical Primate Research Centre, 2280GH Rijswijk, The Netherlands.
World J Hepatol. 2015 Jan 27;7(1):53-69. doi: 10.4254/wjh.v7.i1.53.
Hepatitis C virus (HCV) infection is characterized by a high propensity for development of life-long viral persistence. An estimated 170 million people suffer from chronic hepatitis caused by HCV. Currently, there is no approved prophylactic HCV vaccine available. With the near disappearance of the most relevant animal model for HCV, the chimpanzee, we review the progression that has been made regarding prophylactic vaccine development against HCV. We describe the results of the individual vaccine evaluation experiments in chimpanzees, in relation to what has been observed in humans. The results of the different studies indicate that partial protection against infection can be achieved, but a clear correlate of protection has thus far not yet been defined.
丙型肝炎病毒（HCV）感染的特点是极易形成终身病毒持续性感染。据估计，有1.7亿人患有由HCV引起的慢性肝炎。目前，尚无获批的预防性HCV疫苗。随着HCV最相关的动物模型黑猩猩几近消失，我们回顾了在HCV预防性疫苗研发方面取得的进展。我们描述了在黑猩猩身上进行的个体疫苗评估实验结果，并与在人类身上观察到的情况进行了对比。不同研究的结果表明，可以实现对感染的部分保护，但迄今为止尚未明确保护的明确关联因素。
